{'fraction_non_alphanumeric': 0.02302158273381295, 'fraction_numerical': 0.0014388489208633094, 'mean_word_length': 5.444444444444445, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Management of chronic hepatitis B and C.

Chronic viral hepatitis caused by hepatitis B, C or 0 may lead to cirrhosis, hepatocellular failure and hepatocellular carcinoma. The morbidity of these diseases has necessitated a prolonged search for effective therapy. Although many antiviral compounds have been evaluated for the treatment of chronic viral hepatitis, few have achieved clinical applicability. Alpha-interferon has been widely studied, and remains the mainstay of treatment. A number of other cytokines, including thymosin, are being evaluated. Nucleoside analogues, alone or in combination with alphainterferon, may prove useful adjuncts to the treatment of chronic hepatitis Band C.